3. Spinal muscular atrophy Clinical trials / Disease details
Clinical trials : 217 / Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04174157 (ClinicalTrials.gov) | September 25, 2018 | 12/9/2019 | Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) | A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy (SMA) | Other: Prospective observational registry;Drug: Zolgensma | AveXis, Inc. | United BioSource, LLC | Recruiting | N/A | N/A | All | 500 | United States;Ireland;Israel;Portugal;Japan |